Protective Effect of Vanillic Acid against Hyperinsulinemia, Hyperglycemia and Hyperlipidemia via Alleviating Hepatic Insulin Resistance and Inflammation in High-Fat Diet (HFD)-Fed Rats

• Published in: Nutrients 2015-12, Vol.7 (12), p.9946-9959
• Main Authors: Chang, Wen-Chang, Wu, James Swi-Bea, Chen, Chen-Wen, Kuo, Po-Ling, Chien, Hsu-Min, Wang, Yuh-Tai, Shen, Szu-Chuan
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Acid resistance; Animals; Body weight; Cell culture; Cell Line; Cell Survival; Cyclooxygenase-2; Diabetes mellitus; Dietary Fats - adverse effects; Fatty acids; Glucose; Glucose tolerance; Glucose transporter; Hepatocytes; Hepatocytes - drug effects; High fat diet; Homeostasis; Hyperglycemia; Hyperglycemia - chemically induced; Hyperglycemia - prevention & control; Hyperinsulinemia; Hyperinsulinism - chemically induced; Hyperinsulinism - prevention & control; Hyperlipidemia; Hyperlipidemias - chemically induced; Hyperlipidemias - prevention & control; Inflammation; Inflammation - drug therapy; Insulin; Insulin resistance; Insulin Resistance - physiology; Lipid metabolism; Liver; Liver - drug effects; Metabolism; Mice; Model testing; Monocyte chemoattractant protein; Monocyte chemoattractant protein 1; Monocytes; Oral administration; Phenolic acids; Phenols; Phenols - toxicity; Protein turnover; Proteins; Rats; Rats, Sprague-Dawley; Rodents; Tumor Necrosis Factor-alpha - pharmacology; Vanillic acid; Vanillic Acid - pharmacology
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu7125514

Excess free fatty acid accumulation from abnormal lipid metabolism results in the insulin resistance in peripheral cells, subsequently causing hyperinsulinemia, hyperglycemia and/or hyperlipidemia in diabetes mellitus (DM) patients. Herein, we investigated the effect of phenolic acids on glucose uptake in an insulin-resistant cell-culture model and on hepatic insulin resistance and inflammation in rats fed a high-fat diet (HFD). The results show that vanillic acid (VA) demonstrated the highest glucose uptake ability among all tested phenolic acids in insulin-resistant FL83B mouse hepatocytes. Furthermore, rats fed HFD for 16 weeks were orally administered with VA daily (30 mg/kg body weight) at weeks 13-16. The results show that levels of serum insulin, glucose, triglyceride, and free fatty acid were significantly decreased in VA-treated HFD rats (p < 0.05), indicating the protective effects of VA against hyperinsulinemia, hyperglycemia and hyperlipidemia in HFD rats. Moreover, VA significantly reduced values of area under the curve for glucose (AUCglucose) in oral glucose tolerance test and homeostasis model assessment-insulin resistance (HOMA-IR) index, suggesting the improving effect on glucose tolerance and insulin resistance in HFD rats. The Western blot analysis revealed that VA significantly up-regulated expression of hepatic insulin-signaling and lipid metabolism-related protein, including insulin receptor, phosphatidylinositol-3 kinase, glucose transporter 2, and phosphorylated acetyl CoA carboxylase in HFD rats. VA also significantly down-regulated hepatic inflammation-related proteins, including cyclooxygenase-2 and monocyte chemoattractant protein-1 expressions in HFD rats. These results indicate that VA might ameliorate insulin resistance via improving hepatic insulin signaling and alleviating inflammation pathways in HFD rats. These findings also suggest the potential of VA in preventing the progression of DM.